1-PHENYL-2-PYRIDINYLALKYL ALCOHOLS DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Russian patent published in 2017 - IPC C07D213/89 C07D401/12 C07D401/14 C07D405/14 C07D413/12 C07D417/12 C07D417/14 A61K31/44 A61P11/00 A61P37/08 

FIELD: pharmacology.

SUBSTANCE: invention relates to a compound of general formula , where: R₁ is selected from the group consisting of: methyl; trifluoromethyl; R₂ is selected from the group consisting of: methyl optionally substituted with cyclopropyl; cyclopentyl; or R₁ and R₂, together with their interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (q) condensed with a phenyl group that carries -OR₁ and -OR₂ groups, where the asterisks indicate carbon atoms shared by such phenyl ring: , R₁₉ is hydrogen; R₃ is one or more substituents independently selected from halogen atoms; Z represents a -(CH₂)_n- group, where n is 0 or 1; A is a saturated and monocyclic (C₃-C₇) heterocycloalkylene group selected from the following list of di-radicals: , , , , , , , , , , where symbols [3] and [4] indicate the points of group A attachment to groups Z and K, respectively; K is selected from the group consisting of: -(CH₂)_mC(O)R₄, where m can be 0 or 1; -C(O)(CH₂)_jR₄, where j can be 1 or 2; -SO₂(CH₂)_pR₄, where p can be 0, 1 or 2; -(CH₂)_ySO₂R₄, where y can be 1 or 2; -(CH₂)_zR₄, where z can be 1; and -C(O)(CH₂)₂SO₂R₄; R₄ is a ring system which is a mono- or bicyclic ring which may be saturated, partially unsaturated or fully unsaturated, selected from phenyl, (C₃-C₈) cycloalkyl, (C₃-C₇) heterocycloalkyl where at least one ring carbon atom is replaced by a heteroatom selected from N, NH and O or heteroaryl, such ring is optionally substituted with one or more R₅, which may be the same or different and which are independently selected from the group consisting of: (C₁-C₆) alkyl, optionally substituted with one or more groups independently selected from the list consisting of: -OH; (C₃-C₇) heterocycloalkyl(C₁-C₄)alkyl where at least one ring carbon atom is replaced by a heteroatom selected from N, NH, O; 5-6 member heteroaryl where at least one ring carbon atom is replaced by a heteroatom selected from N and O; -OR₆ group, where R₆ is selected from the group consisting of (C₁-C₆) haloalkyl; -SO₂R₇ group, where R₇ is (C₁-C₄) alkyl; and methyl optionally substituted with one or more (C₃-C₇) cycloalkyls; halogen atoms; CN; NR₈R₉, where R₈ and R₉ are different or identical and independently selected from the group consisting of: H; (C₁-C₄) alkylen-NR₁₃ R₁₄, where R₁₃ and R₁₄ are different or identical and independently selected from the group consisting of: a (C₁-C₆) alkyl, or they form a saturated (C₃-C₇) heterocyclic ring together with the nitrogen atom to which they are attached; -SO₂R₁₅ group, where R₁₅ is selected from the group consisting of: (C₁-C₄) alkyl; -C(O)OR₁₇ group, where R₁₇ is selected from the group consisting of: (C₁-C₆) alkyl; or they form, together with the nitrogen atom to which they are attached, a saturated or partially saturated heterocyclic ring which is optionally substituted by one or more (C₁-C₆) alkyl; (C₁-C₂) alkylene-NR₈R₉, as mentioned above; COR₁₀, where R₁₀ is (C₁-C₆) alkyl; oxo; -SO₂R₁₁, where R₁₁ is (C₁-C₄) alkyl or NR₈R₉, where R₈ and R₉ are as above; -COOR₁₂, where R₁₂ is H, (C₁-C₄) alkyl or (C₁-C₄) alkylene-NR₈R₉, where R₈ and R₉ are as above; and -CONR₈R₉, where R₈ and R₉ are as above; where R₆, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₇ and R₁₉ groups in each case may have the same or different value if more than one group is present; and their N-oxide derivatives on the pyridine ring or their pharmaceutically acceptable salts. The compound is a phosphodiesterase 4 (PDE4) enzyme inhibitors.

EFFECT: improved properties.

19 cl, 26 tbl, 36 ex